The FDA offers a controversial solution to the biosimilars name game

John Carroll

The industry has been wrestling for years now over naming the first wave of building on the coast of the American drug industry. A lot of companies that develop , and that group includes some major corporations, wanted to use the same generic–or nonproprietary–names as the branded drugs, looking to make it easier to carve their way into some blockbuster drug franchises. And a lot of those major brand franchisors wanted something completely different, forcing the biosimilar crowd to market these drugs like a new arrival–a costly and time consuming affair that would help limit any discounting that may have to come after biosimilar competition hits.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS